These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12451232)

  • 21. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.
    Kim SC; Wakwe W; Higginbotham LB; Mathews DV; Breeden CP; Stephenson AC; Jenkins J; Strobert E; Price K; Price L; Kuhn R; Wang H; Yamniuk A; Suchard S; Farris AB; Pearson TC; Larsen CP; Ford ML; Suri A; Nadler S; Adams AB
    Am J Transplant; 2017 May; 17(5):1182-1192. PubMed ID: 28097811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model.
    Kanmaz T; Fechner JJ; Torrealba J; Kim HT; Dong Y; Oberley TD; Schultz JM; Bloom DD; Katayama M; Dar W; Markovits J; Schuler W; Hu H; Hamawy MM; Knechtle SJ
    Transplantation; 2004 Mar; 77(6):914-20. PubMed ID: 15077037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.
    Kirk AD; Burkly LC; Batty DS; Baumgartner RE; Berning JD; Buchanan K; Fechner JH; Germond RL; Kampen RL; Patterson NB; Swanson SJ; Tadaki DK; TenHoor CN; White L; Knechtle SJ; Harlan DM
    Nat Med; 1999 Jun; 5(6):686-93. PubMed ID: 10371508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
    Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
    J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients.
    Cho CS; Burkly LC; Fechner JH; Kirk AD; Oberley TD; Dong Y; Brunner KG; Peters D; Tenhoor CN; Nadeau K; Yagci G; Ishido N; Schultz JM; Tsuchida M; Hamawy MM; Knechtle SJ
    Transplantation; 2001 Aug; 72(4):587-97. PubMed ID: 11544416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking the CD80 and CD86 costimulation molecules: lessons to be learned from animal models.
    Jonker M; Ossevoort And MA; Vierboom M
    Transplantation; 2002 Jan; 73(1 Suppl):S23-6. PubMed ID: 11810057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
    Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
    J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates.
    Xu H; Tadaki DK; Elster EA; Burkly LC; Berning JD; Cruzata F; Kampen RL; Montgomery SP; Patterson NB; Harlan DM; Kirk AD
    Transplantation; 2002 Oct; 74(7):940-3. PubMed ID: 12394834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys.
    Bîrsan T; Hausen B; Higgins JP; Hubble RW; Klupp J; Stalder M; Celniker A; Friedrich S; O'Hara RM; Morris RE
    Transplantation; 2003 Jun; 75(12):2106-13. PubMed ID: 12829920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation.
    Schuler W; Bigaud M; Brinkmann V; Di Padova F; Geisse S; Gram H; Hungerford V; Kleuser B; Kristofic C; Menninger K; Tees R; Wieczorek G; Wilt C; Wioland C; Zurini M
    Transplantation; 2004 Mar; 77(5):717-26. PubMed ID: 15021835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts.
    Haanstra KG; Sick EA; Ringers J; Wubben JA; Kuhn EM; Boon L; Jonker M
    Transplantation; 2005 Jun; 79(11):1623-6. PubMed ID: 15940054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model.
    Xu H; Elster E; Batty D; Berning J; Burkly L; Kampen R; Swanson S; Tadaki D; Harlan D; Kirk A
    Transplant Proc; 2001; 33(1-2):223-4. PubMed ID: 11266788
    [No Abstract]   [Full Text] [Related]  

  • 33. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
    Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
    Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance.
    Phillips NE; Markees TG; Mordes JP; Greiner DL; Rossini AA
    J Immunol; 2003 Mar; 170(6):3015-23. PubMed ID: 12626555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector.
    Ziller C; Stoeckel F; Boon L; Haegel-Kronenberger H
    Gene Ther; 2002 May; 9(9):537-46. PubMed ID: 11973629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.
    Kurtz J; Raval F; Vallot C; Der J; Sykes M
    Blood; 2009 Apr; 113(15):3475-84. PubMed ID: 19179471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody.
    Pierson RN; Chang AC; Blum MG; Blair KS; Scott MA; Atkinson JB; Collins BJ; Zhang JP; Thomas DW; Burkly LC; Miller GG
    Transplantation; 1999 Dec; 68(11):1800-5. PubMed ID: 10609959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
    Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
    J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.